- Home
- APLM vs PETZ Comparison
APLM vs PETZ Comparison
Compare APLM & PETZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- PETZ
- Stock Information
- Founded
- APLM 2016
- PETZ 2002
- Country
- APLM United States
- PETZ China
- Employees
- APLM N/A
- PETZ N/A
- Industry
- APLM Blank Checks
- PETZ Steel/Iron Ore
- Sector
- APLM Finance
- PETZ Industrials
- Exchange
- APLM Nasdaq
- PETZ Nasdaq
- Market Cap
- APLM 12.3M
- PETZ 12.9M
- IPO Year
- APLM N/A
- PETZ 2017
- Fundamental
- Price
- APLM $7.02
- PETZ $1.15
- Analyst Decision
- APLM Strong Buy
- PETZ
- Analyst Count
- APLM 2
- PETZ 0
- Target Price
- APLM $425.00
- PETZ N/A
- AVG Volume (30 Days)
- APLM 7.4K
- PETZ 5.0K
- Earning Date
- APLM 03-04-2025
- PETZ 12-17-2024
- Dividend Yield
- APLM N/A
- PETZ N/A
- EPS Growth
- APLM N/A
- PETZ N/A
- EPS
- APLM N/A
- PETZ N/A
- Revenue
- APLM $2,101,000.00
- PETZ $3,278,453.00
- Revenue This Year
- APLM N/A
- PETZ N/A
- Revenue Next Year
- APLM N/A
- PETZ N/A
- P/E Ratio
- APLM N/A
- PETZ N/A
- Revenue Growth
- APLM 70.54
- PETZ 2.46
- 52 Week Low
- APLM $6.38
- PETZ $1.01
- 52 Week High
- APLM $80.50
- PETZ $1.74
- Technical
- Relative Strength Index (RSI)
- APLM 37.88
- PETZ 44.66
- Support Level
- APLM $6.70
- PETZ $1.13
- Resistance Level
- APLM $7.60
- PETZ $1.23
- Average True Range (ATR)
- APLM 0.70
- PETZ 0.06
- MACD
- APLM -0.03
- PETZ -0.00
- Stochastic Oscillator
- APLM 22.30
- PETZ 16.67
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.